Small but Important Differences Seen Between Rosuvastatin, Atorvastatin
By Lori Solomon HealthDay Reporter
WEDNESDAY, Oct. 30, 2024 -- There are small but important differences in risk for some clinical outcomes associated with rosuvastatin and atorvastatin, according to a study published online Oct. 29 in Annals of Internal Medicine.
Shiyu Zhou, M.D., from Southern Medical University in Guangzhou, China, and colleagues compared the real-world effectiveness and safety of rosuvastatin and atorvastatin. The analysis included 285,680 eligible participants identified from the China Renal Data System (CRDS) and U.K. Biobank (UKB) databases.
The researchers found that six-year all-cause mortality was lower for rosuvastatin than for atorvastatin (2.57 versus 2.83 per 100 person-years in the CRDS database and 0.66 versus 0.90 per 100 person-years in the UKB database). Differences in cumulative incidence were −1.03 percent in the CRDS database and −1.38 percent in the UKB database. Rosuvastatin conferred lower risks for the secondary outcomes of major adverse cardiovascular events and major adverse liver outcomes. The risk for developing type 2 diabetes mellitus was higher in the UKB database with rosuvastatin, but the two medications carried similar risks for developing chronic kidney disease and other statin-related adverse effects.
"Rosuvastatin might be associated with cardiovascular and mortality benefits that need to be weighed against the risk for development of type 2 diabetes mellitus," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Muscle Ultrasound Can Detect Insulin Resistance
MONDAY, June 30, 2025 -- Muscle ultrasound can detect insulin resistance and lower muscle mass, according to a study published online June 12 in the Journal of Ultrasound...
Disparities Seen in Continuous Glucose Monitor Rx by Language Preference
FRIDAY, June 27, 2025 -- For patients with type 2 diabetes (T2D), disparities in continuous glucose monitor (CGM) prescriptions are seen by language preference, with less access...
ADA: Insulin Efsitora Noninferior to Glargine for Reducing HbA1c in Adults With Type 2 Diabetes
FRIDAY, June 27, 2025 -- Once-weekly insulin efsitora alpha (efsitora) is noninferior to once-daily insulin glargine (glargine) for reducing glycated hemoglobin (HbA1c) among...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.